Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.500
0.00 (0.00%)
At close: Feb 26, 2026, 4:00 PM EST
1.510
+0.010 (0.67%)
After-hours: Feb 26, 2026, 4:18 PM EST
Lexicon Pharmaceuticals Employees
Lexicon Pharmaceuticals had 103 employees as of December 31, 2024. The number of employees decreased by 182 or -63.86% compared to the previous year.
Employees
103
Change (1Y)
-182
Growth (1Y)
-63.86%
Revenue / Employee
$688,000
Profits / Employee
-$665,796
Market Cap
640.63M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103 | -182 | -63.86% |
| Dec 31, 2023 | 285 | 150 | 111.11% |
| Dec 31, 2022 | 135 | 48 | 55.17% |
| Dec 31, 2021 | 87 | 9 | 11.54% |
| Dec 31, 2020 | 78 | -106 | -57.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 409 |
| Allogene Therapeutics | 229 |
| Rigel Pharmaceuticals | 164 |
| Vor Biopharma | 154 |
| Ocugen | 95 |
| Neumora Therapeutics | 95 |
| Design Therapeutics | 55 |
| Fulcrum Therapeutics | 45 |
LXRX News
- 8 hours ago - Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 - GlobeNewsWire
- 19 days ago - Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - GlobeNewsWire
- 27 days ago - Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - GlobeNewsWire
- 4 weeks ago - Lexicon Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary - GlobeNewsWire
- 5 weeks ago - Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain - GlobeNewsWire
- 5 weeks ago - Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure - PRNewsWire
- 5 weeks ago - Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha